跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
4-ALS
首页
药物
4-ALS
4-ALS
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
US 7968746 B2
申请人: EDISON PHARMACEUTICALS INC
优先权: 2008
US
10 件公开
THE PEPTIDOMIMETIC COMPOUND (R)-2-AMINO-N-((S)-L-(((S)-5-AMINO-L-(3-BENZYL-1,2,4-OXADIAZOL-5-YL)PENTYL)AMINO)-3-(4-HYDROXY-2,6-DIMETHYLPHENYL)-1-OXOPROPAN-2-YL)-5-GUANIDINOPENTANAMIDE FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS
EP 3986401 B1
申请人: STEALTH BIOTHERAPEUTICS INC
优先权: 2019
CN
EP
US
WO
9 件公开
NOVEL MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY
EP 3867267 A1
申请人: FUNDAMENTAL PHARMA GMBH
优先权: 2018
CN
EP
US
WO
5 件公开
TREATMENTS FOR AMYOTROPHIC LATERAL SCLEROSIS USING DAZUCORILANT
EP 4608402 A1
申请人: CORCEPT THERAPEUTICS INC
优先权: 2022
CN
EP
US
WO
5 件公开
US 20250288580 A1
申请人: CORCEPT THERAPEUTICS INC
优先权: 2025
US
US 20250381178 A1
申请人: CORCEPT THERAPEUTICS INC
优先权: 2025
US
ACTIVATION OF HISTONE DEACETYLASE 1 (HDAC1) PROTECTS AGAINST DNA DAMAGE AND INCREASES NEURONAL SURVIVAL
US 2010075926 A1
申请人: TSAI LI-HUEI
优先权: 2008
CN
US
WO
4 件公开
Method for treating neurodegenerative diseases
US 10272070 B2
申请人: UNIV LELAND STANFORD JUNIOR
优先权: 2015
US
4 件公开
Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states
US 10898458 B2
申请人: MICELLE BIOPHARMA INC
优先权: 2017
US
4 件公开
Method of promoting survival and/or function of a motor neuron and related agents, uses and methods
US 12662672 B2
申请人: AGENCY SCIENCE TECH & RES
优先权: 2019
CN
EP
US
3 件公开
COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING NEURODEGENERATIVE DISEASES WITH DIABETES
EP 4547255 A4
申请人: ARIBIO CO LTD
优先权: 2022
CN
EP
US
3 件公开
COMBINATION THERAPY OF TRADITIONAL CHINESE AND MODERN MEDICINE FOR TREATMENT OF PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS
US 20260021150 A1
申请人: INTEGRATED MOLECULAR MEDICINE LTD
优先权: 2024
CN
US
WO
3 件公开
第 1 / 6 页
上一页
下一页
药物
反馈